By Fineline Cube 
China-based Betta Pharmaceuticals (SHE: 300558) announced a strategic partnership with fellow domestic firm BioRay Biopharmaceutical. Through this collaboration, Betta has secured exclusive distribution and commercialization rights to BioRay’s Anruize, a biosimilar of Roche’s Herceptin (trastuzumab), across Greater China, including mainland China, Hong Kong, Macau, and Taiwan. Additionally, the agreement grants Betta regulatory filing, commercialization, and post-marketing development rights to BioRay’s HS627, an investigational biosimilar of Roche’s Perjeta (pertuzumab), in the same region. Financial terms of the partnership were not disclosed.
Anruize and HS627 Overview
Anruize received marketing approval in China in 2023. HS627 is currently in the market filing stage in the country. This partnership is expected to enhance Betta Pharmaceuticals’ oncology product portfolio and expand its market presence in the region.-Fineline Info & Tech